Streetbeat News

CRVO

CervoMed Inc.

https://www.cervomed.com

Industry

Biotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Open

1.89

Mkt cap

16M

Volume

601K

High

1.95

P/E Ratio

-0.88

52-wk high

26.38

Low

1.81

Div yield

N/A

52-wk low

1.81

CervoMed Inc. has granted equity awards to two new employees as an inducement under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

December 12, 2024 | 12:15 pm

CervoMed Inc.'s stock plummeted by 77% following the failure of a midstage trial for a treatment targeting dementia with Lewy bodies (DLB).

Portfolio Pulse from

December 10, 2024 | 3:30 pm

CervoMed announced that its Phase 2b clinical trial of Neflamapimod in patients with Dementia with Lewy Bodies did not show statistically significant effects compared to placebo on primary and secondary endpoints at 16 weeks.

Portfolio Pulse from

December 10, 2024 | 12:15 pm

CervoMed has received Orphan Drug Designation from the U.S. FDA for its drug neflamapimod, aimed at treating frontotemporal dementia. This designation highlights the significant unmet need in this area and the potential of neflamapimod in treating multiple neurological disorders.

Portfolio Pulse from

November 27, 2024 | 12:15 pm

CervoMed has completed the last patient visit in its RewinD-LB Phase 2b clinical trial for neflamapimod, targeting early-stage dementia with Lewy bodies. Topline data from the trial is expected in December 2024.

Portfolio Pulse from

November 12, 2024 | 12:15 pm

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on age-related neurologic disorders, will participate in investor conferences in November.

Portfolio Pulse from

November 07, 2024 | 1:45 pm

CervoMed Inc. has completed the last patient visit in its Phase 2b trial of neflamapimod for early-stage dementia with Lewy bodies. The company plans to report topline data in December 2024, with promising potential for cognitive and motor function improvement.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:18 pm

CervoMed Inc. (NASDAQ:CRVO) will present findings on neflamapimod for treating dementia with Lewy bodies at the 17th Clinical Trials on Alzheimer's Disease Conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:16 pm

Chardan Capital has initiated coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and set a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 6:38 pm

CervoMed (NASDAQ:CRVO) reported better-than-expected Q2 2024 results with an EPS of $(0.27) beating the estimate of $(0.42) and sales of $3.29 million surpassing the $2.08 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.